Results 41 to 50 of about 34,512 (245)

IDH1 Non-Canonical Mutations and Survival in Patients with Glioma

Diagnostics, 2021
Background: Non-canonical mutations of the isocitrate dehydrogenase (IDH) genes have been described in about 20–25% and 5–12% of patients with WHO grade II and III gliomas, respectively.
Enrico Franceschi, Dario De Biase, Vincenzo Di Nunno, Annalisa Pession, Alicia Tosoni, Lidia Gatto, Giovanni Tallini, Michela Visani, Raffaele Lodi, Stefania Bartolini, Alba Ariela Brandes   +10 more
doaj   +1 more source

Significance and Impact of Changing WHO Classification Systems on Glial Tumors with Special Reference to IDH1 Mutation in Resource-Limited Setups

Asian Pacific Journal of Cancer Biology, 2023
Objectives: To reclassify glial neoplasms according to the 2021 WHO CNS tumor classification and to study the expression pattern of Isocitrate dehydrogenase 1 (IDH1) mutation by immunohistochemistry(IHC) and to categorize these tumors on the basis of ...
Divya Singh, Vatsala Misra, Kachnar Varma   +2 more
doaj   +1 more source

IDH1(R132H) Immunoexpression in Glioma

Advanced Medical Journal, 2018
Background and objectives: Gliomas are the most common type of primary brain tumors. They result from accumu-- lation of multiple genetic alterations. Isocitrate dehydrogenase 1 mutations are detected in gliomas. This study aimed to assess IDH1 immunoexpression in different types of gliomas and to correlate the results with patient’s age, gender, tumor
Nyan Saeed Omer, Jalal Ali Jalal, Ava Tahir Ismael   +2 more
openaire   +2 more sources

NIMG-42LOWER BRAIN NETWORK EFFICIENCY IN IDH1 WILD TYPE (IDH-WT) MALIGNANT ASTROCYTOMA COMPARED TO IDH1 MUTANT (IDH1-M) [PDF]

Neuro-Oncology, 2015
We previously demonstrated that patients with IDH1-WT compared to IDH1-M malignant astrocytoma exhibited worse cognitive function. We hypothesized that this is due to greater lesion momentum that may preclude compensatory brain reorganization. Therefore, in the present study, we examined the structural connectome of patients with IDH1-M and -WT tumors ...
Shelli R. Kesler, Kyle R. Noll, Jeffrey S. Wefel, Daniel P. Cahill, Ganesh Rao   +4 more
openaire   +2 more sources

Clinical Utility of Ivosidenib in the Treatment of IDH1-Mutant Cholangiocarcinoma: Evidence To Date

Cancer Management and Research, 2023
Pedro Luiz Serrano Uson Junior,1– 3 Mitesh J Borad1 1Mayo Clinic Cancer Center, Mayo Clinic, Phoenix, AZ, USA; 2HCOR, Hospital do Coração, Sao Paulo, Brazil; 3Center for Personalized Medicine, Hospital Israelita Albert Einstein, Sao Paulo ...
Uson Junior PLS, Borad MJ
doaj  

Mutant IDH1: An immunotherapeutic target in tumors [PDF]

OncoImmunology, 2014
The discovery of driver mutations in cancers has raised interest in their suitability as immunotherapeutic targets. A recent study demonstrates that a point mutation in isocitrate dehydrogenase 1 (IDH1R132H), expressed in gliomas and other tumors, is presented on human MHC class II and induces a mutation-specific CD4+ antitumor T cell response in ...
Theresa Schumacher, Wolfgang Wick, Michael Platten, Lukas Bunse   +3 more
openaire   +3 more sources

Expression of LOC285758, a potential long non-coding biomarker, is methylation-dependent and correlates with glioma malignancy grade

Radiology and Oncology, 2017
Identifying the early genetic drivers can help diagnose glioma tumours in their early stages, before becoming malignant. However, there is emerging evidence that disturbance of epigenetic mechanisms also contributes to cell’s malignant transformation and
Matjasic Alenka, Popovic Mara, Matos Bostjan, Glavac Damjan   +3 more
doaj   +1 more source

IDH1 and IDH2 mutations in lung adenocarcinomas: Evidences of subclonal evolution

Cancer Medicine, 2020
Background Selective IDH1 and IDH2 inhibitors have been approved for targeted therapy of acute myeloid leukemia. Clinical trials for solid tumors with IDH1 and IDH2 (IDH1/2) mutations are ongoing.
Erika F. Rodriguez, Federico De Marchi, Parvez M. Lokhandwala, Deborah Belchis, Rena Xian, Christopher D. Gocke, James R. Eshleman, Peter Illei, Ming‐Tseh Li   +8 more
doaj   +1 more source

Impact of IDH1 Mutation on Long-Term Survival in Patients with Diffuse Glioma

Central Asian Journal of Medical Sciences, 2019
Objectives: Diffuse brain gliomas are common primary brain tumor associated with a poor prognosis. In this study, we aimed to determine the impact of IDH1 mutation status on long term survival.
Enkhee Ochirjav, Tuul Baldandorj, Gheeyoung Choe, Bayarmaa Enkhbat   +3 more
doaj   +1 more source

Sustained Clinical Response to Ivosidenib in Previously Treated Patients with Advanced Intrahepatic Cholangiocarcinoma Harboring an IDH1 R132 Mutation: Two Case Reports

Case Reports in Oncology
Introduction: Patients with progressing intrahepatic cholangiocarcinoma (iCCA) harboring an isocitrate dehydrogenase 1 (IDH1) mutation who received ivosidenib showed a median progression-free survival (PFS) benefit of 1.3 months compared to placebo in ...
Christian Müller, Sabine Franke, Timo Reisländer, Verena Keitel, Marino Venerito   +4 more
doaj   +1 more source